Pulmonx AeriSeal converts 75.8% of evaluable patients to valve-eligible status in CONVERT trial
LUNG•Pulmonx said published CONVERT trial results showed AeriSeal enabled 75.8% of evaluable patients with severe emphysema to become eligible for Zephyr Valve treatment. Enrollment continues in the pivotal CONVERT II trial.




